SlideShare a Scribd company logo
1 of 63
Download to read offline
VITAMIN A & VISUAL CYCLE
MODERATOR-DR SUDHA SEETHARAM
PRESENTER-DR RAVNEET CHADHA
INTRODUCTION
 VITAMINS:-
Vitamins may be regarded as organic
compounds required in the diet in small
amounts to perform specific biological
functions for normal maintenance of optimum
growth and health of the organism.
VITAMIN A & VISUAL CYCLE
WHAT IS VITAMIN A?
• The term “vitamin A” makes it sound like there is one
particular nutrient called “vitamin A”, but this is not true.
It is a broad group of related nutrients.
• Vitamin A is a broad term for group of unsaturated
nutritional organic compounds, that
includes retinol, retinal, retinoic acid, and
several provitamin A carotenoids, among which beta-
carotene is the most important.
THUS,
VITAMIN A IS AN Essential fat soluble vitamin occuring in
the following forms:
 Preformed
 Retinoids (retinal, retinol, retinoic acid)
 Found in animal products
 Provitamin A
 Carotenoids
 Must be converted to retinoid form
 Found in plant products
HISTORY
 It is recorded in history that HIPPOCRATES cured night
blindness(about 500 B.C)
 He prescribed to the patients Ox liver(in honey)which is
now known to contain high quantity of vitamin A.
 By 1917, Elmer McCollum et al at the University of
Wisconsin–Madison, studied the role of fats in the diet
and discovered few accessory factors. These "accessory
factors" were termed "fat soluble" in 1918 and later
"vitamin A" in 1920.
 In 1919, Harry Steenbock (University of Wisconsin)
proposed a relationship between yellow plant pigments
(beta-carotene) and vitamin A.
 In 1931, Swiss chemist Paul Karrer described the
chemical structure of vitamin A.
 Vitamin A was first synthesized in 1947 by two Dutch
chemists, David Adriaan van Dorp and Jozef Ferdinand
Arens.
Structure of vitamin A
NOMENCLATURE
PROVITAMIN A : β-Carotene
VITAMIN A1 : Retinol ( Vitamin A alcohol)
VITAMIN A2 : 3 –Dehydro-retinol
VITAMIN A ALDEHYDE : Retinal
VITAMIN A ACID : Retinoic acid
VITAMIN A ESTER : Retinyl ester
NEO VITAMIN A : Stereoisomer of Vitamin A1, has 70
–80% of biological activity of Vitamin A1.
 CHEMISTRY
• Vitamin A is composed of ‘β-IONONE RING’ (CYCLOHEXENYL)
to which ‘POLY ISOPRENOID SIDE CHAIN’ is attached
 Polyisoprenoid chain –all trans configuration, contains 4
double bonds, has 2 methyl groups with terminal carbon
having ‘R’ group
 ‘R’ Group –alcohol/aldehyde/acid
 β-Ionone ring –contains 1 double bond with 3 methyl
groups
Retinol: -(CH2OH)
-found in animal tissues as
‘Retinyl esters’ with long
chain fatty acids
•Retinal: -(CHO)
-Aldehyde derived from
oxidation of retinol by ‘retinal
reductase’ requiring
NAD/NADP
-Retinol & Retinal are inter-
convertible
•Retinoic acid : -(COOH)
-Acid derived from oxidation of
retinal
-Retinoic acid cannot be
reduced in body therefore
cannot form retinal or retinol.
•β-Carotene :
-Hydrolysed by β-carotene
dioxygenase in presence of
oxygen & bile salts to two
molecules of retinal.
Sources of vitamin A
• Animal : Fish Liver oil, Butter, Milk, Cheese,
Egg Yolk
• Plant : All Yellow –Orange –Red –Dark Green
fruits & vegetables like Tomatoes, Carrots,
Spinach, Papayas, Mangoes, corn, sweet
potatoes.
RECOMMENDED DIETARY
ALLOWANCE
 Unit of activity is expressed as ‘RETINAL
EQUIVALENT’ (R.E.) / ‘INTERNATIONAL UNIT’ (I.U.)
1 Retinal Equivalent = 1μg of Retinol OR 6 μg of β-
carotene
1 I.U. = 0.3 μg of Retinol OR 0.34 μg of Retinyl acetate
OR 0.6 μg of β-carotene
Infants & Children : 400 t0 600 μg/day
Adults (Men & Women) : 600 to 800 μg/day
Pregnancy & Lactation : 1000 to 1200 μg/day
ABSORPTION,TRANSPORT AND STORAGE OF VITAMIN A
VISUAL CYCLE
 The term “visual cycle” was coined by George Wald in the
mid 1900’s to describe the ability of the eye to “re-cycle”
vitamin A for the synthesis of visual pigments(wald,1968)
 As originally proposed (Wald,1968),the rod visual cycle
requires the involvement of both retina and the retinal
pigment epithelium(RPE) in order to properly process the
retinal chromophore released from bleached rod
pigment(or rhodopsin)
INTRODUCTION
 The visual cycle is the biological conversion of a photon into
an electrical signal in the retina.
 The processing of visual information begins in the retina with
the detection of light by photoreceptor cells.
 The photoreceptor cells involved in vision are :
1. rods.
2. cones.
 Both the rods and cones contain chemicals that decompose
on exposure to light and in the process, excite the nerve fibres
leading from the eye.
 light sensitive chemical in the rods is called rhodopsin and
that in the cones is called cone pigments/colour pigments
Anatomy of photoreceptors
RODS:-
 Cylindrical stuctures
 Length:40-60 microns
 Diameter:2 micron
 For peripheral vision and
scotopic vision
 Contain visual purple
(Rhodopsin)
 120 million
 Absent in fovea
Each rod is composed
of four structures
namely:
1. outer segment
2. Inner segment
3. Cell body
4. Synaptic terminal
Outer segment : Outer
segment is cylindrical,
transversely striated and
contains rhodopsin
The photosensitive pigment
rhodopsin is present in
membranous discs.
There are about 1000 discs in
each rod.
The outer segment of rod cell
is constantly renewed by the
formation of new discs.(3-4/hr)
 Inner segment: connected to outer
segment by means of modified cilium.
 Contains organelles with large number
of mitochondria.
 Cell body: also called rod granule,
contains the nucleus.
 Synaptic terminal: synapses with
dendrites of bipolar cells and horizontal
cells. Synaptic vesicles present in the
synaptic terminal contain the
neurotransmitter glutamate.
CONES:
 Central and colour vision
 Length :35-40 microns
 Diameter: 5microns
 Contain Iodopsin
 6.5 million
 Highest density in fovea
(199000 cones /mm2)
 Each cone is composed
of four structures
namely:
1. outer segment
2. Inner segment
3. Cell body
4. Synaptic terminal
 Outer segment: smaller and
conical
 Contains saccules (infoldings
of cell membrane)
counterparts of rod discs.
 Renewal of outer segment of
cone is a slow process and it
differs form that in rods.
.
Inner segment: connected to
outer segment with modified
cilium. Contain organelles and
mitochondria.
Cell body: also called cone
granule, possesses the nucleus.
Synaptic terminal: synaptic
vesicle present in the synaptic
terminal possess the
neurotransmitter, glutamate
50.4 Membranuous structures of the outer
segments of a rod and cone
Physiology of vision
 The main mechanisms are:
1. Initiation of vision(phototransduction)
2. Processing and transmission of visual sensations
3. Visual perception
Photochemistry of vision
 Will be discussed under the following headings:
1. Rhodopsin-retinal visual cycle in the rods.
• Rhodopsin and its decomposition by light energy.
• Reformation of rhodopsin.
• Role of vitamin A in the formation of rhodopsin.
• Excitation of rod when rhodopsin is activated.
2. Colour vision in the cones.
Chemical basis of visual process
 The photopigments present in the rods and cones
decompose on exposure to light, in the process, excite
the nerve fibers through generation of electrical activity
and impulses in the retina.
 Photopigments:
 Rhodopsin/visual purple present in rods.
 Colour pigments/cone pigments(porphyropsin,iodopsin
and cyanopsin) present in cones.
Rhodopsin –retinal visual cycle in the rods.
Rhodopsin and its decomposition by light energy:
• The outer segment of the rod that projects into the
pigment layer of retina has a concentration of about 40%
of light sensitive pigments called Rhodopsin or visual
purple.
• Rhodopsin = scotopsin(protein) + retinal(carotenoid
protein).
• Retinal is present in the form of 11-cis retinal known as
retinene.
• cis form of retinal is important because only this form can
bind with scotopsin to synthesize rhodopsin.
Photochemical changes in rhodopsin:
1.Bleaching of rhodopsin:
 When exposed to light, the colour of rhodopsin changes
from red to yellow by a process known as bleaching.
 Bleaching occurs in a few milliseconds and many unstable
intermediates are formed during the process.
2. Reformation of rhodopsin:
changes occuring in rhodopsin
 Light rhodopsin barthorhodopsin
lumirhodopsin
RHODOPSIN BLEACHING
metarhodopsin I
metarhodopsin II
scotopsin
11-cis retinal isomerase all-trans retinal
REFORMATION
11-cis retinol isomerase all trans retinol
Phototransduction
The transduction of light into a neural signal takes
place in the outer segment of a retinal rod or cone
photoreceptor
Fig. 50.6 Movement of sodium and potassium ions through
the inner and outer segments of the rod
VITAMIN A & VISUAL CYCLE
VITAMIN A & VISUAL CYCLE
VISUAL CYCLE-COLOUR VISION
Cones are specialised in bright & colour vision
 Colour vision is governed by 3 colour sensitive pigments :
 -Porphyropsin (Red)
 -Iodopsin (Green)
 -Cyanopsin (Blue)
 All these are retinal-opsin complexes
 When bright light strikes the retina →one or more of these
pigments are bleached, depending on the colour of light
→pigment (s) dissociating into All-trans-retinal & Opsin
 Differential bleaching
 Nerve impulse generated by visual cascade causes perception
of specific colour
 Receptor potential of the photoreceptors is locally graded
potential i.e it does not propagate
 The receptor potential does not follow all or none law .
 The receptor potential generated in the photoreceptors
is transmitted by electronic conduction to the other cells
of retina i.e horizontal cells,bipolar cells,amacrine cells
and ganglion cells
 The ganglion cells transmit the visual signals by means of
action potential
FUNCTIONS OF VITAMIN A
 VISION
 GENE TRANSCRIPTION
 IMMUNE FUNCTION
 EMBRYONIC DEVELOPMENT AND REPRODUCTION
 BONE METABOLISM
 HAEMATOPOESIS
 SKIN AND CELLULAR HEALTH
 ANTIOXIDANT ACTIVITY
VITAMIN A DEFICIENCY
 Most susceptible populations:
 Preschool children with low F&V intake
 Urban poor
 Older adults
 Alcoholism
 Liver disease (limits storage)
 Fat malabsorption
Vitamin A deficiency may result from :
 -Dietary insufficiency of Vitamin A / Precursors
 -Interference with absorption from intestines
 eg: diarrhoea, malabsorption syndrome, bile salt
deficiency
 -Defect in the transport due to protein malnutrition –
‘Kwashiorkar’
 -Defect in the storage due to diseases of liver
Tissues chiefly affected –‘Epithelial’ principally which
are not normally keratinised
Includes epithelium of respiratory tract,
gastrointestinal tract, genitourinary tract, eye &
paraocular glands, salivary glands, accessory glands
of tongue & buccal cavity and pancreas
Fundamental change: Metaplasia of normal non-
keratinised living cells into keratinising type of
epithelium
OCULAR MANIFESTATIONS OF
VITAMIN A DEFICIENCY
 XEROPHTHALMIA
The term xerophthalmia was given by a joint WHO and
USAID committee in 1976 to cover all the ocular
manifestations of vitamin A deficiency including the
structural changes affecting the conjunctiva, cornea and
retina and also the biophysical disorders of retinal rods
and cones functions.
WHO CLASSIFICATION (1982)
XEROPHTHALMIA CLASSIFICATION(modified)
 XN Night blindness
 X1A Conjunctival xerosis
 X1B Bitot’s spots
 X2 Corneal xerosis
 X3A Corneal ulceration /keratomalacia affecting less than
1/3rd corneal surface
 X3B Corneal ulceration /keratomalacia affecting more
than 1/3rd corneal surface
 XS Corneal scar due to xerophthalmia.
 XF Xerophthalmic fundus.
XN :NIGHT BLINDNESS(Nyctalopia)
 Earliest symptom of xerophthalmia in children
 Diminished visual acuity in ‘dim light’(Insufficient
adaptation to darkness)
 Defective rhodopsin function.
X1A CONJUNCTIVAL XEROSIS
Characterised by:
 One or more patches of dry, lustreless,nonwettable
conjunctiva.
 Interpalpebral conjunctiva(commonly temporal
quadrants)
 Severe cases involves the entire bulbar conjunctiva.
 Desribed as ‘emerging like sand banks at receding
tide’when child ceases to cry
 Can lead to conjunctival thickening,wrinkling and
pigmentation.
X1B BITOT’S SPOTS
 Bilateral
 Bulbar conjunctiva in the interpalpebral area
 Commonly in temporal quadrant.
 Triangular greyish/silvery white spots/plaques.
 Firmly adherent to conjunctiva
 Foamy keratinised epithelium(corynebacterium xerosis)
X2 CORNEAL XEROSIS
 Dry lustreless appearance of cornea
 Earliest change is punctate keratopathy
 Begins in the lower nasal quadrant
 Bilateral punctate corneal epithelial erosions
 Can progress to epithelial defects
 Reversible on treatment
X3A & X3B CORNEAL ULCERATION
/KERATOMALACIA
 Stromal defects occur in late stages due to colliquative
necrosis leading to corneal ulceration ,softening (melting)
and destruction of cornea(keratomalacia)
 Corneal ulcers may be small or large
 Stromal defects involving less than 1/3rd cornea usually
heal leaving some useful vision
 Large stromal defects commonly result in blindness.
 Small ulcers
 1-3mm
 Occur peripherally
 Circular
 Steep margins and
sharply demarcated
 Large ulcers
 More than 3mm
 Occur centrally
 Involve entire cornea
XS CORNEAL SCAR
 Healing of stromal defects results in corneal scarring
 Size of the corneal scar depends on the size and density
of corneal defect.
XF XEROPHTHALMIC FUNDUS
 Uncommon in occurance
 Typical seed like lesions
 Whitish/yellow
 Raised
 Scattered uniformly over part of fundus
 At the level of optic disc.
 FFA reveals these dots to be focal retinal pigment
epithelial defects
CONTND
 Rarely these patients can present with scotomas
corresponding to the area of retinal involvement
 Respond to vitamin A therapy with scotoma disappearing
in 1-2 weeks and retinal lesions fading in 1-4 months.
AGE GROUP DOSE DURATION
1.All patients above
one year
2.<1 yr of age or <8
kg weight
3.Women of
reproductive age
group
-less severe
- severe
2,00,000 IU
Half the dose i.e
1,00,000 IU
10,000 IU
2,00,000 IU
Day of presentation,
next day and 2-3
weeks later
2 weeks
VITAMIN A THERAPY
 Treatment schedules apply to all stages of active
xerophthalmia
1. Oral therapy (Recommended)
2. Parenteral therapy: IN CASES OF
-severe disease
-unable to take oral feeds
-Repeated vomiting and diarrhoea
-malabsorption
 Intramuscular injections of water miscible vit A
preparation
 Dose – 1,00,000 IU(Half the oral dose)
 Local ocular therapy-
 Intense lubrication-instilled every 3-4 hours
 Topical retinoic acid
 Treatment of keratomalacia and corneal ulcer
 Treatment of corneal perforation
PROPHYLAXIS AGAINST XEROPHTHALMIA
 1.Short term approach
-Periodic administration of vitamin A supplements
-WHO recommended ,universal distribution schedule of vit A
for prevention is as follows:
i) Infants <6months (not being breastfed)—50,000 IU
ii)Infants 6-12 months and any child <8kg – 1,00,000 IU
every 3-6months
iii)Children over 1 year and under 6 years --- 2,00,000 IU orally
every 6 months
iv)Lactating mothers – 2,00,000 IU orally once at delivery or
during next 2 months to maintain level of vitamin A in breast
milk
PROPHYLAXIS
1.Infants <1 year
(not being
breastfed)
2.Infants 6-12
months and any
child <8kg
3. Children > 1
year and < 6
years
4. Lactating
mothers
50,000 IU
1,00,000 IU
2,00,000 IU
2,00,000 IU
Every 3-6 months
Every 6 months
once at delivery
or during next 2
months to
maintain level of
vitamin A in
breast milk
ctnd
 Under vitamin A supplementation program through
Reproductive and child health program(RCH) and now
National Rural Health Mission(NRHM)
-- Children between 9 and 36 months of age are to be
provided with vitamin A solution every 6 months starting
with 1,00,000 IU at 9 months of age along with measles
vaccination and subsequently 2,00,000 IU every 6 months
till 36 months of age.
 2.Medium term approach-
- fortification of food with Vit A
 3. Long term approach-
- Promotion of adequate intake of Vit A rich foods in high
risk groups particularly preschool aged children on a
periodic basis and to mothers within 6-8 weeks after
childbirth
- Other measures like nutritional education,social
marketing,home or community garden programs and
measures to improve food security.
HYPERVITAMINOSIS A
 Ingestion of large amounts of preformed vitaminA from
the diet,supplement intake or medications
 Acute:
 Single doses of >3,00,000 IU
 Headache ,Blurred vision,nausea
,vomiting,drowsiness,irritability i.e signs of raised
ICP(Benign intracranial hypertension)
 Serum vit a values-200-1000 IU/dl
Benign intracranial hypertension
 Increased intracranial pressure
 Idiopathic
 Headache (m.c),vomiting,pulsatile tinnitus
 Diplopia(compression of 6th nerve)
 Rarely compression of 3rd n 4th nerve
 Papillaedema
 visual field defects
 Long standing pappilledema leads to optic atrophy.
 Chronic – long-term megadose; possible permanent
damage ( >50,000 IU/day for several wks)
 Bone and muscle pain
 Loss of appetite
 Skin disorders
 Headache
 Dry skin
 Hair loss
 Increased liver size
-Manifestations reversible when vitamin A discontinued
Thank you

More Related Content

What's hot

UREA CYCLE
UREA CYCLEUREA CYCLE
UREA CYCLEYESANNA
 
Water soluble vitamins
Water soluble vitaminsWater soluble vitamins
Water soluble vitaminsIAU Dent
 
Vitamin A chemistry, functions and deficiency
Vitamin A chemistry, functions and deficiencyVitamin A chemistry, functions and deficiency
Vitamin A chemistry, functions and deficiencyNamrata Chhabra
 
THIAMINE (B1)
THIAMINE (B1)THIAMINE (B1)
THIAMINE (B1)YESANNA
 
Extraocular muscles
Extraocular musclesExtraocular muscles
Extraocular musclesOm Patel
 
BIOTIN (B7)
BIOTIN (B7)BIOTIN (B7)
BIOTIN (B7)YESANNA
 
DIGESTION & ABSORPTION OF PROTEINS
DIGESTION & ABSORPTION OF PROTEINSDIGESTION & ABSORPTION OF PROTEINS
DIGESTION & ABSORPTION OF PROTEINSYESANNA
 
Light and Dark Adaptation
Light and Dark AdaptationLight and Dark Adaptation
Light and Dark AdaptationTrisruta Deb
 
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISM
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISMGLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISM
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISMYESANNA
 
Vitamin E
Vitamin EVitamin E
Vitamin EYESANNA
 
Digestion and absorption of proteins
Digestion and absorption of proteinsDigestion and absorption of proteins
Digestion and absorption of proteinsAshok Katta
 

What's hot (20)

Vitamin A
Vitamin AVitamin A
Vitamin A
 
UREA CYCLE
UREA CYCLEUREA CYCLE
UREA CYCLE
 
Water soluble vitamins
Water soluble vitaminsWater soluble vitamins
Water soluble vitamins
 
Eye
EyeEye
Eye
 
Vitamin A chemistry, functions and deficiency
Vitamin A chemistry, functions and deficiencyVitamin A chemistry, functions and deficiency
Vitamin A chemistry, functions and deficiency
 
Ocular biochemistry
Ocular biochemistry Ocular biochemistry
Ocular biochemistry
 
THIAMINE (B1)
THIAMINE (B1)THIAMINE (B1)
THIAMINE (B1)
 
Visual pathway
Visual pathwayVisual pathway
Visual pathway
 
Extraocular muscles
Extraocular musclesExtraocular muscles
Extraocular muscles
 
BIOTIN (B7)
BIOTIN (B7)BIOTIN (B7)
BIOTIN (B7)
 
Dark adaptation
Dark adaptationDark adaptation
Dark adaptation
 
DIGESTION & ABSORPTION OF PROTEINS
DIGESTION & ABSORPTION OF PROTEINSDIGESTION & ABSORPTION OF PROTEINS
DIGESTION & ABSORPTION OF PROTEINS
 
Accomodation reflex
Accomodation reflexAccomodation reflex
Accomodation reflex
 
Light and Dark Adaptation
Light and Dark AdaptationLight and Dark Adaptation
Light and Dark Adaptation
 
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISM
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISMGLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISM
GLYCOGENOLYSIS & REGULATION OF GLYCOGEN METABOLISM
 
Vitamin E
Vitamin EVitamin E
Vitamin E
 
Protein Metabolism
Protein MetabolismProtein Metabolism
Protein Metabolism
 
Nitrogen balance
Nitrogen balanceNitrogen balance
Nitrogen balance
 
Digestion and absorption of proteins
Digestion and absorption of proteinsDigestion and absorption of proteins
Digestion and absorption of proteins
 
Bile
BileBile
Bile
 

Viewers also liked

fat soluble vitamins
fat soluble vitaminsfat soluble vitamins
fat soluble vitaminsManoj Arockia
 
Floods in pakistan
Floods in pakistanFloods in pakistan
Floods in pakistanAnup Tiwari
 
Fat soluble vitanine. mostafa askar
Fat soluble vitanine. mostafa askarFat soluble vitanine. mostafa askar
Fat soluble vitanine. mostafa askarMostafa Askar
 
Vitamin A and its deficiency
Vitamin A and its deficiencyVitamin A and its deficiency
Vitamin A and its deficiencyReshma Ann Mathew
 
Vitamin a deficiency HYPERVITAMINOSIS A
Vitamin a deficiency HYPERVITAMINOSIS AVitamin a deficiency HYPERVITAMINOSIS A
Vitamin a deficiency HYPERVITAMINOSIS ADr Pankaj Yadav
 
I mbbs plasma proteins tutorial
I mbbs plasma proteins tutorialI mbbs plasma proteins tutorial
I mbbs plasma proteins tutorialMehnaga Vasu
 
Vitamin A Deficiency & Eye
Vitamin A Deficiency & EyeVitamin A Deficiency & Eye
Vitamin A Deficiency & EyeAnkit Punjabi
 
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicity
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicityVitamin a presentation, Vitamin A Deficiency, Vitamin A toxicity
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicityDhruvendra Pandey
 
Vitamin & Mineral Deficiency
Vitamin & Mineral DeficiencyVitamin & Mineral Deficiency
Vitamin & Mineral DeficiencyShahin Hameed
 

Viewers also liked (15)

fat soluble vitamins
fat soluble vitaminsfat soluble vitamins
fat soluble vitamins
 
Floods in pakistan
Floods in pakistanFloods in pakistan
Floods in pakistan
 
Fat soluble vitanine. mostafa askar
Fat soluble vitanine. mostafa askarFat soluble vitanine. mostafa askar
Fat soluble vitanine. mostafa askar
 
Vitamin A and its deficiency
Vitamin A and its deficiencyVitamin A and its deficiency
Vitamin A and its deficiency
 
Vitamin a deficiency HYPERVITAMINOSIS A
Vitamin a deficiency HYPERVITAMINOSIS AVitamin a deficiency HYPERVITAMINOSIS A
Vitamin a deficiency HYPERVITAMINOSIS A
 
I mbbs plasma proteins tutorial
I mbbs plasma proteins tutorialI mbbs plasma proteins tutorial
I mbbs plasma proteins tutorial
 
Vitamin A Deficiency & Eye
Vitamin A Deficiency & EyeVitamin A Deficiency & Eye
Vitamin A Deficiency & Eye
 
Vitamin A
Vitamin AVitamin A
Vitamin A
 
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicity
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicityVitamin a presentation, Vitamin A Deficiency, Vitamin A toxicity
Vitamin a presentation, Vitamin A Deficiency, Vitamin A toxicity
 
Paraproteinemia
ParaproteinemiaParaproteinemia
Paraproteinemia
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Vitamin A Deficiency
Vitamin A DeficiencyVitamin A Deficiency
Vitamin A Deficiency
 
Vitamin & Mineral Deficiency
Vitamin & Mineral DeficiencyVitamin & Mineral Deficiency
Vitamin & Mineral Deficiency
 
Vitamin A
Vitamin AVitamin A
Vitamin A
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 

Similar to VITAMIN A & VISUAL CYCLE

Similar to VITAMIN A & VISUAL CYCLE (20)

FAT SOLUBLE VITMAINS final.ppt
FAT SOLUBLE VITMAINS final.pptFAT SOLUBLE VITMAINS final.ppt
FAT SOLUBLE VITMAINS final.ppt
 
Physiology of Retina
Physiology of RetinaPhysiology of Retina
Physiology of Retina
 
VITAMIN A_MBBS_II.pptx
VITAMIN A_MBBS_II.pptxVITAMIN A_MBBS_II.pptx
VITAMIN A_MBBS_II.pptx
 
Retina.avinas
Retina.avinasRetina.avinas
Retina.avinas
 
Photo-chemistry of Vision
Photo-chemistry of VisionPhoto-chemistry of Vision
Photo-chemistry of Vision
 
2-VITAMIN A _ VISUAL CYCLE.pdf
2-VITAMIN A _ VISUAL CYCLE.pdf2-VITAMIN A _ VISUAL CYCLE.pdf
2-VITAMIN A _ VISUAL CYCLE.pdf
 
Vitamin A
Vitamin AVitamin A
Vitamin A
 
Class 5.pptx
Class 5.pptxClass 5.pptx
Class 5.pptx
 
Fat Soluble Vitamins
Fat Soluble VitaminsFat Soluble Vitamins
Fat Soluble Vitamins
 
VITAMIN A.pptx
VITAMIN A.pptxVITAMIN A.pptx
VITAMIN A.pptx
 
vitamin A.pptx,, metabolism and function
vitamin A.pptx,, metabolism and functionvitamin A.pptx,, metabolism and function
vitamin A.pptx,, metabolism and function
 
Vitamin A
Vitamin AVitamin A
Vitamin A
 
Vitamin a
Vitamin aVitamin a
Vitamin a
 
Vitamins a
Vitamins aVitamins a
Vitamins a
 
Fat soluble vitamins
Fat soluble vitaminsFat soluble vitamins
Fat soluble vitamins
 
3 Fat soluble vitamins.pptx
3 Fat soluble vitamins.pptx3 Fat soluble vitamins.pptx
3 Fat soluble vitamins.pptx
 
02 Vitamin A.ppt
02 Vitamin A.ppt02 Vitamin A.ppt
02 Vitamin A.ppt
 
13.sakina vitamin a &amp; d
13.sakina vitamin a &amp;  d13.sakina vitamin a &amp;  d
13.sakina vitamin a &amp; d
 
Retina physiology
Retina physiologyRetina physiology
Retina physiology
 
2-Vitamin A.ppt
2-Vitamin A.ppt2-Vitamin A.ppt
2-Vitamin A.ppt
 

More from Laxmi Eye Institute (20)

Important trials in Glaucoma
Important trials in GlaucomaImportant trials in Glaucoma
Important trials in Glaucoma
 
Congenital glaucoma
Congenital glaucomaCongenital glaucoma
Congenital glaucoma
 
Ocular pharmacology
Ocular pharmacologyOcular pharmacology
Ocular pharmacology
 
Supranuclear pathways and lesions
Supranuclear pathways and lesionsSupranuclear pathways and lesions
Supranuclear pathways and lesions
 
IOL power calculation special situations
IOL power calculation special situations IOL power calculation special situations
IOL power calculation special situations
 
Corneal dystrophy
Corneal dystrophy Corneal dystrophy
Corneal dystrophy
 
Ice syndrome
Ice syndromeIce syndrome
Ice syndrome
 
Scleritis a case presentation
Scleritis a case presentationScleritis a case presentation
Scleritis a case presentation
 
Visual pathway
Visual pathway Visual pathway
Visual pathway
 
CCP
CCPCCP
CCP
 
Ocular tb
Ocular tbOcular tb
Ocular tb
 
Causes of low vision in adult
Causes of low vision in adultCauses of low vision in adult
Causes of low vision in adult
 
Macular hole
Macular holeMacular hole
Macular hole
 
Trial set
Trial setTrial set
Trial set
 
ASSESMENT OF VISUAL ACUITY IN CHILDREN
ASSESMENT OF VISUAL ACUITY IN CHILDRENASSESMENT OF VISUAL ACUITY IN CHILDREN
ASSESMENT OF VISUAL ACUITY IN CHILDREN
 
INTRAOCULAR FOREIGN BODY
INTRAOCULAR FOREIGN BODYINTRAOCULAR FOREIGN BODY
INTRAOCULAR FOREIGN BODY
 
Malignant glaucoma
Malignant glaucomaMalignant glaucoma
Malignant glaucoma
 
Lasers in Glaucoma
Lasers in GlaucomaLasers in Glaucoma
Lasers in Glaucoma
 
Uveitic Glaucoma
Uveitic GlaucomaUveitic Glaucoma
Uveitic Glaucoma
 
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trialCentral Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
 

Recently uploaded

ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLyons Health
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborHealth Catalyst
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementIris Thiele Isip-Tan
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxMUKESH PADMANABHAN
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdfCompliatric Where Compliance Happens
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxHanineHassan2
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxPamela McKinney
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11crzljavier
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024Traumasoft LLC
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxEMADABATHINI PRABHU TEJA
 

Recently uploaded (20)

ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and Labor
 
Annual Training
Annual TrainingAnnual Training
Annual Training
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
person with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptxperson with disability and pwd act ppt.pptx
person with disability and pwd act ppt.pptx
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptx
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptx
 

VITAMIN A & VISUAL CYCLE

  • 1. VITAMIN A & VISUAL CYCLE MODERATOR-DR SUDHA SEETHARAM PRESENTER-DR RAVNEET CHADHA
  • 2. INTRODUCTION  VITAMINS:- Vitamins may be regarded as organic compounds required in the diet in small amounts to perform specific biological functions for normal maintenance of optimum growth and health of the organism.
  • 4. WHAT IS VITAMIN A? • The term “vitamin A” makes it sound like there is one particular nutrient called “vitamin A”, but this is not true. It is a broad group of related nutrients. • Vitamin A is a broad term for group of unsaturated nutritional organic compounds, that includes retinol, retinal, retinoic acid, and several provitamin A carotenoids, among which beta- carotene is the most important.
  • 5. THUS, VITAMIN A IS AN Essential fat soluble vitamin occuring in the following forms:  Preformed  Retinoids (retinal, retinol, retinoic acid)  Found in animal products  Provitamin A  Carotenoids  Must be converted to retinoid form  Found in plant products
  • 6. HISTORY  It is recorded in history that HIPPOCRATES cured night blindness(about 500 B.C)  He prescribed to the patients Ox liver(in honey)which is now known to contain high quantity of vitamin A.  By 1917, Elmer McCollum et al at the University of Wisconsin–Madison, studied the role of fats in the diet and discovered few accessory factors. These "accessory factors" were termed "fat soluble" in 1918 and later "vitamin A" in 1920.
  • 7.  In 1919, Harry Steenbock (University of Wisconsin) proposed a relationship between yellow plant pigments (beta-carotene) and vitamin A.  In 1931, Swiss chemist Paul Karrer described the chemical structure of vitamin A.  Vitamin A was first synthesized in 1947 by two Dutch chemists, David Adriaan van Dorp and Jozef Ferdinand Arens.
  • 8. Structure of vitamin A NOMENCLATURE PROVITAMIN A : β-Carotene VITAMIN A1 : Retinol ( Vitamin A alcohol) VITAMIN A2 : 3 –Dehydro-retinol VITAMIN A ALDEHYDE : Retinal VITAMIN A ACID : Retinoic acid VITAMIN A ESTER : Retinyl ester NEO VITAMIN A : Stereoisomer of Vitamin A1, has 70 –80% of biological activity of Vitamin A1.
  • 9.  CHEMISTRY • Vitamin A is composed of ‘β-IONONE RING’ (CYCLOHEXENYL) to which ‘POLY ISOPRENOID SIDE CHAIN’ is attached  Polyisoprenoid chain –all trans configuration, contains 4 double bonds, has 2 methyl groups with terminal carbon having ‘R’ group  ‘R’ Group –alcohol/aldehyde/acid  β-Ionone ring –contains 1 double bond with 3 methyl groups
  • 10. Retinol: -(CH2OH) -found in animal tissues as ‘Retinyl esters’ with long chain fatty acids •Retinal: -(CHO) -Aldehyde derived from oxidation of retinol by ‘retinal reductase’ requiring NAD/NADP -Retinol & Retinal are inter- convertible
  • 11. •Retinoic acid : -(COOH) -Acid derived from oxidation of retinal -Retinoic acid cannot be reduced in body therefore cannot form retinal or retinol. •β-Carotene : -Hydrolysed by β-carotene dioxygenase in presence of oxygen & bile salts to two molecules of retinal.
  • 12. Sources of vitamin A • Animal : Fish Liver oil, Butter, Milk, Cheese, Egg Yolk • Plant : All Yellow –Orange –Red –Dark Green fruits & vegetables like Tomatoes, Carrots, Spinach, Papayas, Mangoes, corn, sweet potatoes.
  • 13. RECOMMENDED DIETARY ALLOWANCE  Unit of activity is expressed as ‘RETINAL EQUIVALENT’ (R.E.) / ‘INTERNATIONAL UNIT’ (I.U.) 1 Retinal Equivalent = 1μg of Retinol OR 6 μg of β- carotene 1 I.U. = 0.3 μg of Retinol OR 0.34 μg of Retinyl acetate OR 0.6 μg of β-carotene Infants & Children : 400 t0 600 μg/day Adults (Men & Women) : 600 to 800 μg/day Pregnancy & Lactation : 1000 to 1200 μg/day
  • 15. VISUAL CYCLE  The term “visual cycle” was coined by George Wald in the mid 1900’s to describe the ability of the eye to “re-cycle” vitamin A for the synthesis of visual pigments(wald,1968)  As originally proposed (Wald,1968),the rod visual cycle requires the involvement of both retina and the retinal pigment epithelium(RPE) in order to properly process the retinal chromophore released from bleached rod pigment(or rhodopsin)
  • 16. INTRODUCTION  The visual cycle is the biological conversion of a photon into an electrical signal in the retina.  The processing of visual information begins in the retina with the detection of light by photoreceptor cells.  The photoreceptor cells involved in vision are : 1. rods. 2. cones.  Both the rods and cones contain chemicals that decompose on exposure to light and in the process, excite the nerve fibres leading from the eye.  light sensitive chemical in the rods is called rhodopsin and that in the cones is called cone pigments/colour pigments
  • 17. Anatomy of photoreceptors RODS:-  Cylindrical stuctures  Length:40-60 microns  Diameter:2 micron  For peripheral vision and scotopic vision  Contain visual purple (Rhodopsin)  120 million  Absent in fovea
  • 18. Each rod is composed of four structures namely: 1. outer segment 2. Inner segment 3. Cell body 4. Synaptic terminal
  • 19. Outer segment : Outer segment is cylindrical, transversely striated and contains rhodopsin The photosensitive pigment rhodopsin is present in membranous discs. There are about 1000 discs in each rod. The outer segment of rod cell is constantly renewed by the formation of new discs.(3-4/hr)
  • 20.  Inner segment: connected to outer segment by means of modified cilium.  Contains organelles with large number of mitochondria.  Cell body: also called rod granule, contains the nucleus.  Synaptic terminal: synapses with dendrites of bipolar cells and horizontal cells. Synaptic vesicles present in the synaptic terminal contain the neurotransmitter glutamate.
  • 21. CONES:  Central and colour vision  Length :35-40 microns  Diameter: 5microns  Contain Iodopsin  6.5 million  Highest density in fovea (199000 cones /mm2)
  • 22.  Each cone is composed of four structures namely: 1. outer segment 2. Inner segment 3. Cell body 4. Synaptic terminal
  • 23.  Outer segment: smaller and conical  Contains saccules (infoldings of cell membrane) counterparts of rod discs.  Renewal of outer segment of cone is a slow process and it differs form that in rods. .
  • 24. Inner segment: connected to outer segment with modified cilium. Contain organelles and mitochondria. Cell body: also called cone granule, possesses the nucleus. Synaptic terminal: synaptic vesicle present in the synaptic terminal possess the neurotransmitter, glutamate
  • 25. 50.4 Membranuous structures of the outer segments of a rod and cone
  • 26. Physiology of vision  The main mechanisms are: 1. Initiation of vision(phototransduction) 2. Processing and transmission of visual sensations 3. Visual perception
  • 27. Photochemistry of vision  Will be discussed under the following headings: 1. Rhodopsin-retinal visual cycle in the rods. • Rhodopsin and its decomposition by light energy. • Reformation of rhodopsin. • Role of vitamin A in the formation of rhodopsin. • Excitation of rod when rhodopsin is activated. 2. Colour vision in the cones.
  • 28. Chemical basis of visual process  The photopigments present in the rods and cones decompose on exposure to light, in the process, excite the nerve fibers through generation of electrical activity and impulses in the retina.  Photopigments:  Rhodopsin/visual purple present in rods.  Colour pigments/cone pigments(porphyropsin,iodopsin and cyanopsin) present in cones.
  • 29. Rhodopsin –retinal visual cycle in the rods. Rhodopsin and its decomposition by light energy: • The outer segment of the rod that projects into the pigment layer of retina has a concentration of about 40% of light sensitive pigments called Rhodopsin or visual purple. • Rhodopsin = scotopsin(protein) + retinal(carotenoid protein). • Retinal is present in the form of 11-cis retinal known as retinene. • cis form of retinal is important because only this form can bind with scotopsin to synthesize rhodopsin.
  • 30. Photochemical changes in rhodopsin: 1.Bleaching of rhodopsin:  When exposed to light, the colour of rhodopsin changes from red to yellow by a process known as bleaching.  Bleaching occurs in a few milliseconds and many unstable intermediates are formed during the process. 2. Reformation of rhodopsin:
  • 31. changes occuring in rhodopsin  Light rhodopsin barthorhodopsin lumirhodopsin RHODOPSIN BLEACHING metarhodopsin I metarhodopsin II scotopsin 11-cis retinal isomerase all-trans retinal REFORMATION 11-cis retinol isomerase all trans retinol
  • 32. Phototransduction The transduction of light into a neural signal takes place in the outer segment of a retinal rod or cone photoreceptor
  • 33. Fig. 50.6 Movement of sodium and potassium ions through the inner and outer segments of the rod
  • 36. VISUAL CYCLE-COLOUR VISION Cones are specialised in bright & colour vision  Colour vision is governed by 3 colour sensitive pigments :  -Porphyropsin (Red)  -Iodopsin (Green)  -Cyanopsin (Blue)  All these are retinal-opsin complexes  When bright light strikes the retina →one or more of these pigments are bleached, depending on the colour of light →pigment (s) dissociating into All-trans-retinal & Opsin  Differential bleaching  Nerve impulse generated by visual cascade causes perception of specific colour
  • 37.  Receptor potential of the photoreceptors is locally graded potential i.e it does not propagate  The receptor potential does not follow all or none law .  The receptor potential generated in the photoreceptors is transmitted by electronic conduction to the other cells of retina i.e horizontal cells,bipolar cells,amacrine cells and ganglion cells  The ganglion cells transmit the visual signals by means of action potential
  • 38. FUNCTIONS OF VITAMIN A  VISION  GENE TRANSCRIPTION  IMMUNE FUNCTION  EMBRYONIC DEVELOPMENT AND REPRODUCTION  BONE METABOLISM  HAEMATOPOESIS  SKIN AND CELLULAR HEALTH  ANTIOXIDANT ACTIVITY
  • 39. VITAMIN A DEFICIENCY  Most susceptible populations:  Preschool children with low F&V intake  Urban poor  Older adults  Alcoholism  Liver disease (limits storage)  Fat malabsorption
  • 40. Vitamin A deficiency may result from :  -Dietary insufficiency of Vitamin A / Precursors  -Interference with absorption from intestines  eg: diarrhoea, malabsorption syndrome, bile salt deficiency  -Defect in the transport due to protein malnutrition – ‘Kwashiorkar’  -Defect in the storage due to diseases of liver
  • 41. Tissues chiefly affected –‘Epithelial’ principally which are not normally keratinised Includes epithelium of respiratory tract, gastrointestinal tract, genitourinary tract, eye & paraocular glands, salivary glands, accessory glands of tongue & buccal cavity and pancreas Fundamental change: Metaplasia of normal non- keratinised living cells into keratinising type of epithelium
  • 42. OCULAR MANIFESTATIONS OF VITAMIN A DEFICIENCY  XEROPHTHALMIA The term xerophthalmia was given by a joint WHO and USAID committee in 1976 to cover all the ocular manifestations of vitamin A deficiency including the structural changes affecting the conjunctiva, cornea and retina and also the biophysical disorders of retinal rods and cones functions.
  • 43. WHO CLASSIFICATION (1982) XEROPHTHALMIA CLASSIFICATION(modified)  XN Night blindness  X1A Conjunctival xerosis  X1B Bitot’s spots  X2 Corneal xerosis  X3A Corneal ulceration /keratomalacia affecting less than 1/3rd corneal surface  X3B Corneal ulceration /keratomalacia affecting more than 1/3rd corneal surface  XS Corneal scar due to xerophthalmia.  XF Xerophthalmic fundus.
  • 44. XN :NIGHT BLINDNESS(Nyctalopia)  Earliest symptom of xerophthalmia in children  Diminished visual acuity in ‘dim light’(Insufficient adaptation to darkness)  Defective rhodopsin function.
  • 45. X1A CONJUNCTIVAL XEROSIS Characterised by:  One or more patches of dry, lustreless,nonwettable conjunctiva.  Interpalpebral conjunctiva(commonly temporal quadrants)  Severe cases involves the entire bulbar conjunctiva.  Desribed as ‘emerging like sand banks at receding tide’when child ceases to cry  Can lead to conjunctival thickening,wrinkling and pigmentation.
  • 46. X1B BITOT’S SPOTS  Bilateral  Bulbar conjunctiva in the interpalpebral area  Commonly in temporal quadrant.  Triangular greyish/silvery white spots/plaques.  Firmly adherent to conjunctiva  Foamy keratinised epithelium(corynebacterium xerosis)
  • 47. X2 CORNEAL XEROSIS  Dry lustreless appearance of cornea  Earliest change is punctate keratopathy  Begins in the lower nasal quadrant  Bilateral punctate corneal epithelial erosions  Can progress to epithelial defects  Reversible on treatment
  • 48. X3A & X3B CORNEAL ULCERATION /KERATOMALACIA  Stromal defects occur in late stages due to colliquative necrosis leading to corneal ulceration ,softening (melting) and destruction of cornea(keratomalacia)  Corneal ulcers may be small or large  Stromal defects involving less than 1/3rd cornea usually heal leaving some useful vision  Large stromal defects commonly result in blindness.
  • 49.  Small ulcers  1-3mm  Occur peripherally  Circular  Steep margins and sharply demarcated  Large ulcers  More than 3mm  Occur centrally  Involve entire cornea
  • 50. XS CORNEAL SCAR  Healing of stromal defects results in corneal scarring  Size of the corneal scar depends on the size and density of corneal defect.
  • 51. XF XEROPHTHALMIC FUNDUS  Uncommon in occurance  Typical seed like lesions  Whitish/yellow  Raised  Scattered uniformly over part of fundus  At the level of optic disc.  FFA reveals these dots to be focal retinal pigment epithelial defects
  • 52. CONTND  Rarely these patients can present with scotomas corresponding to the area of retinal involvement  Respond to vitamin A therapy with scotoma disappearing in 1-2 weeks and retinal lesions fading in 1-4 months.
  • 53. AGE GROUP DOSE DURATION 1.All patients above one year 2.<1 yr of age or <8 kg weight 3.Women of reproductive age group -less severe - severe 2,00,000 IU Half the dose i.e 1,00,000 IU 10,000 IU 2,00,000 IU Day of presentation, next day and 2-3 weeks later 2 weeks VITAMIN A THERAPY  Treatment schedules apply to all stages of active xerophthalmia 1. Oral therapy (Recommended)
  • 54. 2. Parenteral therapy: IN CASES OF -severe disease -unable to take oral feeds -Repeated vomiting and diarrhoea -malabsorption  Intramuscular injections of water miscible vit A preparation  Dose – 1,00,000 IU(Half the oral dose)
  • 55.  Local ocular therapy-  Intense lubrication-instilled every 3-4 hours  Topical retinoic acid  Treatment of keratomalacia and corneal ulcer  Treatment of corneal perforation
  • 56. PROPHYLAXIS AGAINST XEROPHTHALMIA  1.Short term approach -Periodic administration of vitamin A supplements -WHO recommended ,universal distribution schedule of vit A for prevention is as follows: i) Infants <6months (not being breastfed)—50,000 IU ii)Infants 6-12 months and any child <8kg – 1,00,000 IU every 3-6months iii)Children over 1 year and under 6 years --- 2,00,000 IU orally every 6 months iv)Lactating mothers – 2,00,000 IU orally once at delivery or during next 2 months to maintain level of vitamin A in breast milk
  • 57. PROPHYLAXIS 1.Infants <1 year (not being breastfed) 2.Infants 6-12 months and any child <8kg 3. Children > 1 year and < 6 years 4. Lactating mothers 50,000 IU 1,00,000 IU 2,00,000 IU 2,00,000 IU Every 3-6 months Every 6 months once at delivery or during next 2 months to maintain level of vitamin A in breast milk
  • 58. ctnd  Under vitamin A supplementation program through Reproductive and child health program(RCH) and now National Rural Health Mission(NRHM) -- Children between 9 and 36 months of age are to be provided with vitamin A solution every 6 months starting with 1,00,000 IU at 9 months of age along with measles vaccination and subsequently 2,00,000 IU every 6 months till 36 months of age.
  • 59.  2.Medium term approach- - fortification of food with Vit A  3. Long term approach- - Promotion of adequate intake of Vit A rich foods in high risk groups particularly preschool aged children on a periodic basis and to mothers within 6-8 weeks after childbirth - Other measures like nutritional education,social marketing,home or community garden programs and measures to improve food security.
  • 60. HYPERVITAMINOSIS A  Ingestion of large amounts of preformed vitaminA from the diet,supplement intake or medications  Acute:  Single doses of >3,00,000 IU  Headache ,Blurred vision,nausea ,vomiting,drowsiness,irritability i.e signs of raised ICP(Benign intracranial hypertension)  Serum vit a values-200-1000 IU/dl
  • 61. Benign intracranial hypertension  Increased intracranial pressure  Idiopathic  Headache (m.c),vomiting,pulsatile tinnitus  Diplopia(compression of 6th nerve)  Rarely compression of 3rd n 4th nerve  Papillaedema  visual field defects  Long standing pappilledema leads to optic atrophy.
  • 62.  Chronic – long-term megadose; possible permanent damage ( >50,000 IU/day for several wks)  Bone and muscle pain  Loss of appetite  Skin disorders  Headache  Dry skin  Hair loss  Increased liver size -Manifestations reversible when vitamin A discontinued